Fluo Labs Inc. is a premarket clinical-stage medical device company on a mission to improve the quality of life for millions of people who suffer from seasonal allergies. Fluo Labs’ founders have decades of industry experience in the development of cutting-edge, light-based medical devices and extensive experience in multiple pharma and biotech therapeutic areas including virology, rhinitis drug therapies, and light therapeutics. The technology has won multiple awards including Gear Diary’s Best of CES 2021 Award, Techlicious’ Top Picks of CES 2021 Award, and Fluo Labs was a P&G Ventures 2021 CES Innovation Challenge finalist. [1]

Figure 1. The Fluo Labs – Treatment

Figure 1 shows According to Fluo Labs, 10 seconds in each nostril 1-2 times a day can reduce allergy-related inflammation. They say their first clinical trial yielded a 31% improvement for allergy sufferers. [2]

Fluo Labs, a medical device company on a mission to improve the quality of life for millions of allergy sufferers, today unveiled Flō, a breakthrough device that promises to dramatically improve the way people manage Allergic Rhinitis (AR) -- more commonly known as hay fever. With a successful clinical trial under its belt, the working prototype treats AR by using light therapy to inhibit the release of histamines and reduce inflammation - effectively acting as a natural antihistamine. Created by a team of experts in the fields of light therapeutics, antihistamines, and nasal steroids, the technology is the result of more than 15 years of cutting-edge research, preclinical and clinical development. Fluo Labs has two additional clinical trials planned and is pursuing FDA approval for the use of the device as an OTC device. Flō is expected to be available for purchase in late 2021. [4]

Reasons to Invest

• Own a piece of a growing global market:
  Over 50 Million Americans and 1 Billion more people worldwide suffer from allergies. The global allergy treatment market is set to reach $40 billion by 2025.
• Feel empowered by our partnership with a leading global life sciences company:
  Their regulatory and marketing expertise, as well as their financial support will help Fluo Labs accelerate its plans to bring innovation to the fast-growing respiratory care category on a global scale.
• Capitalize on powerful market drivers and opportunities:
  
  • Little innovation in the allergy care space leaves huge gaps of unmet consumer needs.
  • Climate change is creating longer and more intense allergy seasons.
  • Limited success of common allergy treatments for 66% of allergy sufferers
  • Consumers are rapidly shifting preferences towards non-medicated solutions.
• Participate in the introduction of a new category -
  and standard - in allergy care as we develop Fluo, our light-based technology designed to reduce allergy symptoms without medication. [3]

References:

1. https://www.globenewswire.com/news-release/2021/08/12/2279747/0/en/Fluo-Labs-Announces-Partnership-With-a-Leading-Global-Life-Sciences-Company.html
2. https://geardiary.com/2021/01/12/fluo-labs-flo-ces-2021/
3. https://www.startengine.com/fluo
4. https://www.prweb.com/releases/fluo_labs_unveils_a_revolutionary_new_device_poised_to_transform_how_people_manage_hay_fever_symptoms/prweb17651248.htm

Cite this article:

Thanusri swetha J (2021), The Fluo Labs – Treatment, pp. 30